Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers

BACKGROUND: The Clinical and Laboratory Standards Institute (CLSI) lowered the Enterobacterales-susceptible/-resistant breakpoints for amikacin in 2023 from ≤16/≥64 mg/L to ≤4/≥16 mg/L and the breakpoints for gentamicin and tobramycin from ≤4/≥16 mg/L to ≤2/≥8 mg/L. Because aminoglycosides are frequ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sader, Helio S, Mendes, Rodrigo E, Kimbrough, John H, Kantro, Valerie, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969732/
https://www.ncbi.nlm.nih.gov/pubmed/36861086
http://dx.doi.org/10.1093/ofid/ofad058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969732/
https://www.ncbi.nlm.nih.gov/pubmed/36861086
http://dx.doi.org/10.1093/ofid/ofad058

Ejemplares similares